Brought to you by 
Canadian biotech Oncolytics raises $2.3mm in IPO
29 Nov 1999
Executive Summary
Synsorb Biotech's subsidiary Oncolytics Inc. of Calgary, Alberta (developing a reovirus as a cancer treatment) has grossed $2.3mm ($Cdn3.4mm) in its initial public offering in Canada. It sold 4mm common shares at $Cdn0.85 apiece.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Canadian biotech Oncolytics raises $2.3mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice